ZYKADIA is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.23.04.2018 בקשה לשינוי משטר מינון - Dose modification for patients with severe hepatic impairment (Child-Pugh C), reduce the dose of ZYKADIA by approximately one-third, rounded to the nearest multiple of the 150 mg dosage strength- New starting dose - 450 mg taken orally once daily with food (instead of 750mg taken on empty stomach).First dose reduction due to adverse reactions- 300 mg taken orally once daily with food, second dose reduction - 150 mg taken orally once daily with food. Discontinue ZYKADIA for patients unable to tolerate 150 mg daily with food.